logo
Sign in

KA Stock Price, Chart, Stats & News

Kineta, Inc.
Save
7.05M
Market cap
Current P/E
Forward P/E

KA chart

1M
3M
1Y
5Y
Loading chart...

Fundamentals

Gross margin
162.93%
Operating margin
-100.09%
Pretax margin
-117.01%
Net margin
-117.43%
Effective tax rate
-0.35%
ROA
-604.99%
ROE
43.75%
D/E
-0.05x
Interest coverage ratio
-48.79x

KA valuation

P/E
P/S
1.62x
P/B
-0.56x
P/CF
-2.72x
P/FCF
-2.59x
P/OCF
-2.72x
PEG
-0.03x
EV multiple
-1.14x

About

Kineta, Inc. is a clinical-stage biotechnology firm dedicated to developing immunotherapies, with a focus on oncology, neuroscience, and biodefense applications. The company engages in partnerships with a variety of entities, including private companies, government bodies, and other industry stakeholders. Among its significant strategic collaborators are Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd.

Similar securities

Based on sector and market capitalization

Report issue